Literature DB >> 2443241

Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.

J Burchell1, S Gendler, J Taylor-Papadimitriou, A Girling, A Lewis, R Millis, D Lamport.   

Abstract

A mucin molecule, which has a molecular weight of greater than 400,000 and which carries tumor associated epitopes recognized by monoclonal antibodies HMFG-1 and HMFG-2, has been purified from human skimmed milk by affinity chromatography followed by passage through a size exclusion column. While treatment of the mucin with hydrogen fluoride for 1 h at 4 degrees C removed the peripheral oligosaccharides, treatment with HF for 3 h at room temperature removed all of its lectin binding ability and revealed a dominant polypeptide of about 68,000. This appears to be the size of the mucin core protein. Monoclonal antibodies have been developed that react with the stripped and partially stripped molecule but not with the intact mucin. From the initial screening on histological sections one of these antibodies, SM-3, reacts with 91% of breast carcinomas but shows little or no reactivity on benign mammary tumors, normal resting, pregnant, or lactating breast. It appears that this monoclonal antibody is reacting with an epitope that is usually masked by oligosaccharide moieties in normal cells but which is exposed, perhaps due to aberrant glycosylation, in malignant cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2443241

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  86 in total

1.  Overview of new treatments for breast cancer.

Authors:  G N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

Review 2.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

3.  Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions.

Authors:  P X Xing; K Reynolds; G A Pietersz; I F McKenzie
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

Review 4.  Lewis x is highly expressed in normal tissues: a comparative immunohistochemical study and literature revision.

Authors:  María V Croce; Marina Isla-Larrain; Martín E Rabassa; Sandra Demichelis; Andrea G Colussi; Marina Crespo; Ezequiel Lacunza; Amada Segal-Eiras
Journal:  Pathol Oncol Res       Date:  2007-07-03       Impact factor: 3.201

5.  The isolation and description of LIF-10: a human tumor cell line derived from a colorectal adenocarcinoma.

Authors:  L Huschtscha; W Bodmer
Journal:  In Vitro Cell Dev Biol       Date:  1990-08

6.  Antibody recognition of a unique tumor-specific glycopeptide antigen.

Authors:  Cory L Brooks; Andrea Schietinger; Svetlana N Borisova; Peter Kufer; Mark Okon; Tomoko Hirama; C Roger Mackenzie; Lai-Xi Wang; Hans Schreiber; Stephen V Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

7.  Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody.

Authors:  M E Verhoeyen; J A Saunders; M R Price; J D Marugg; S Briggs; E L Broderick; S J Eida; A T Mooren; R A Badley
Journal:  Immunology       Date:  1993-03       Impact factor: 7.397

8.  Characterization of cell surface antigens expressed in the HMA-1 breast cancer cell line.

Authors:  N Ohuchi; Y Harada; T Masuko; S Matano; S Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  Significance of MUC1 and MUC2 mucin expression in colorectal cancer.

Authors:  Y Ajioka; L J Allison; J R Jass
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

10.  Epitope expression on the breast epithelial mucin.

Authors:  R L Ceriani; J A Peterson; E W Blank; D T Lamport
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.